PCN272 OBINUTUZUMAB TREATMENT ON 1ST LINE HIGH AND INTERMEDIATE RISK FOLLICULAR LYMPHOMA. SHORT-TERM REDUCTION OF RELAPSED OR REFRACTORY DIRECT MEDICAL COSTS IN ARGENTINA AND CHILE.

Abstract

To estimate the potential epidemiology and economic impact of Obinutuzumab on avoided relapsed and refractory Follicular Lymphoma (RRFL) patients due to its introduction in the Chilean and Argentinian 1st line High and Intermediate Risk Follicular Lymphoma (1LFL HR+IR) population. A budget impact model was developed to assess the reduction in RRFL incidence and costs as a result of 1st line treatment with Obinutuzumab (O) instead of Rituximab (R), in Chile and Argentina. Age-specific NHL incidence rates from GLOBOCAN were applied to countries population estimates to determine its annual patients. 1st Line and RRFL local data was collected using institutional surveys, databases and published literature sources. The Follicular Lymphoma International Prognostic Index (FLIPI) was used to define high and intermediate risk proportions within the 1LFL cases. Progression-free survival (PFS) curves of R and O regimes were used to quantify the projected decline in the number of 1LFL HR+IR relapsing to RRFL over a 5-year period. Incremental benefit of O over R was based on the PFS derived from the Gallium study. RRFL direct medical costs were calculated using publicly available prices and adapting local treatment algorithms from both countries. Costs were shown in US Dollars using the official exchange rate for June 1, 2019. Among 1LFL HR+IR incident patients over 1 year, assuming 100% treatment uptake of O compared to 100% of R, the number of of RRFL cases projected to be prevented by the Chilean and Argentinian health systems is a total of 213 over 5 years (46%). This represented a sum of us$12.377.289 of costs savings. 1LFL HR+IR treatment with O instead of R can lead to reductions in RRFL incidence over the short-term. This may be translated into substantial economic benefits in Chile and Argentina in the near future.